CTLA4 and breast cancer: Checkpoint inhibitors, anti-CTLA4 and anti-PD1 have been reported to elicit anti-cancer responses, although studies in the ER+ luminal BC subtype, demonstrate that due to the low titer of TILs in these patients, it is not the therapy of choice (422).